Literature DB >> 18073146

Characterization of fluoroquinolone resistance mechanisms and their correlation with the degree of resistance to clinically used fluoroquinolones among Escherichia coli isolates.

Tsung-Ming Chang1, Po-Liang Lu, Hsuan-Hui Li, Chung-Yu Chang, Tun-Chieh Chen, Lin-Li Chang.   

Abstract

DNA sequencing and real-time PCR were used to evaluate the gyrA and parC mutations, AcrAB efflux pump over-expression, and their correlation with high-level resistance to fluoroquinolones in 74 fluoroquinolone-resistant clinical Escherichia coli isolates recently collected in Taiwan. RAPD analysis revealed high clonal diversity. Isolates with four to five mutations (especially Ser83Leu, Asp87Asn [or Asp87Tyr], and Ala93Thr in gyrA and Ser80Ile and Glu84Gly in parC) had increased resistance levels. The acrA gene was over-expressed in 51% of 74 resistant isolates. The trend was towards increased fluoroquinolone MICs in isolates with both multiple mutations in the quinolone-resistance determining region (QRDR) and over-expression of the AcrAB efflux pump. Furthermore, acrA gene over-expression was significantly correlated with cross-resistance to beta-lactams including piperacillin, amoxicillin, clavulanic acid, and cefazolin. In conclusion, mutations in the QRDR are the primary mechanism for increasing fluoroquinolone resistance, and in combination with efflux pump over-expression, contribute to high-level resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18073146     DOI: 10.1179/joc.2007.19.5.488

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  12 in total

1.  Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli.

Authors:  Renu Singh; Michelle C Swick; Kimberly R Ledesma; Zhen Yang; Ming Hu; Lynn Zechiedrich; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

Review 2.  Origin and proliferation of multiple-drug resistance in bacterial pathogens.

Authors:  Hsiao-Han Chang; Ted Cohen; Yonatan H Grad; William P Hanage; Thomas F O'Brien; Marc Lipsitch
Journal:  Microbiol Mol Biol Rev       Date:  2015-03       Impact factor: 11.056

3.  Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility.

Authors:  Jennifer H Han; Warren B Bilker; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Neil O Fishman; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2013-08-23       Impact factor: 3.254

4.  Epidemiology and characteristics of Escherichia coli sequence type 131 (ST131) from long-term care facility residents colonized intestinally with fluoroquinolone-resistant Escherichia coli.

Authors:  Jennifer H Han; Charles Garrigan; Brian Johnston; Irving Nachamkin; Connie Clabots; Warren B Bilker; Evelyn Santana; Pam Tolomeo; Joel Maslow; Janice Myers; Lesley Carson; Ebbing Lautenbach; James R Johnson
Journal:  Diagn Microbiol Infect Dis       Date:  2016-11-28       Impact factor: 2.803

Review 5.  Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions.

Authors:  Rachel M Greenblatt; Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-21       Impact factor: 3.254

6.  In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.

Authors:  Lorenzo Drago; Lucia Nicola; Roberto Mattina; Elena De Vecchi
Journal:  BMC Microbiol       Date:  2010-04-21       Impact factor: 3.605

7.  Temporal changes in resistance mechanisms in colonizing Escherichia coli isolates with reduced susceptibility to fluoroquinolones.

Authors:  Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Warren B Bilker; Ebbing Lautenbach
Journal:  Diagn Microbiol Infect Dis       Date:  2013-05-27       Impact factor: 2.803

8.  Risk factors for the development of gastrointestinal colonization with fluoroquinolone-resistant Escherichia coli in residents of long-term care facilities.

Authors:  Jennifer H Han; Joel Maslow; Xiaoyan Han; Sharon X Xie; Pam Tolomeo; Evelyn Santana; Lesley Carson; Ebbing Lautenbach
Journal:  J Infect Dis       Date:  2013-08-28       Impact factor: 5.226

9.  Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.

Authors:  Patrizia Spigaglia; Fabrizio Barbanti; Thomas Louie; Frédéric Barbut; Paola Mastrantonio
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

10.  Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin.

Authors:  Takae Shimizu; Kazuki Harada; Yasushi Kataoka
Journal:  Acta Vet Scand       Date:  2013-05-01       Impact factor: 1.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.